Q32 Bio Welcomes Dr. Adrien Sipos as Interim Chief Medical Officer

Q32 Bio Inc., a clinical-stage biotechnology company listed on Nasdaq as QTTB, recently announced a significant leadership change within its ranks. Dr. Adrien Sipos, M.D., Ph.D., has been appointed as the Interim Chief Medical Officer as the company continues its mission to develop innovative therapies for alopecia areata and other autoimmune diseases. Dr. Sipos takes over from Dr. Jason Campagna, M.D., Ph.D., who will be leaving the company after contributing to the advancement of their promising treatment, bempikibart.

Leadership Transition

The appointment of Dr. Sipos is seen as a strategic move for Q32 Bio, especially as it prepares for the next stages of its ongoing SIGNAL-AA Phase 2a clinical trial. Dr. Jodie Morrison, CEO of Q32 Bio, expressed her enthusiasm, stating, "Adrien has a proven track record of success in roles that span clinical development and medical affairs supporting commercial launches." Dr. Morrison emphasized that Dr. Sipos’ deep expertise in immunology will be invaluable in advancing bempikibart, a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling, forming a novel approach for treating alopecia areata.

Dr. Sipos also shared her excitement about joining Q32 Bio at a pivotal time. She noted, "It’s an exciting time to join Q32 Bio as we advance the SIGNAL-AA Phase 2a clinical trial and approach topline results from the Part B portion in the first half of next year." Dr. Sipos added that the clinical data thus far has shown promising potential for the treatment of patients in need of innovative solutions for their health challenges.

Extensive Experience in Immunology

Before her role at Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc. Here, she provided guidance on clinical development and medical affairs initiatives across various therapeutic areas, partnering with both emerging and established biopharmaceutical firms. Prior to her tenure at PRAXICO, Dr. Sipos held significant positions at Biogen, Inc., where she was instrumental in establishing a global clinical development organization for late-stage immunology. Her involvement at companies like Sanofi Genzyme and Eli Lilly has further solidified her reputation as an expert in the field.

Dr. Sipos holds a Ph.D. in Clinical Immunology from the Hungarian Academy of Sciences and has completed postdoctoral research at the University of Oxford. Her impressive academic background is complemented by her medical residency at Debrecen Medical University specializing in clinical immunology and endocrine care. Additionally, she is actively involved with the Beth Israel Deaconess Medical Center's Institutional Biosafety Committee.

Q32 Bio's Commitment to Innovation

Q32 Bio focuses on targeting potent regulators of the adaptive immune system to develop robust therapies for diseases like alopecia areata, which affects around 700,000 individuals in the United States alone. The company is currently advancing bempikibart (ADX-914) through its Phase 2 program, aiming to re-regulate immune functions and provide new treatment options. The recognition of IL-7 and TSLP pathways in numerous autoimmune disorders underpins the scientific foundation of Q32 Bio’s innovative strategies.

As the company navigates this transition and pushes forward its clinical milestones, stakeholders are eager to see how Dr. Sipos’ leadership will influence the progression of Q32 Bio’s initiatives. With a solid background and a shared vision for patient impact, her leadership could lead to significant breakthroughs in the treatment landscape for alopecia areata and beyond.

For further information about Q32 Bio and its unique therapies, please visit Q32Bio.com.